Skeletal muscle as an artificial endocrine tissue

Best Practice & Research. Clinical Endocrinology & Metabolism
Geoffrey Goldspink

Abstract

Muscle has the ability to take up and express engineered genes and, because it is a post-mitotic tissue, their half-life of expression is prolonged. Although muscle is not regarded as a secretory tissue, in many cases, the gene products enter the systemic circulation. The possibility exists, therefore, of using this approach to alter levels of endocrine and paracrine factors. As a therapeutic procedure, this method has an advantage over the administration of the peptide/protein, which has a relatively short half-life and requires repeated injections. Engineered genes in plasmid or viral vectors under the control of a muscle-specific regulatory sequence may be introduced by intramuscular injection or by the introduction of transfected myoblasts. The latter is also being used in bioreactors to produce medicinal proteins/peptides in vitro as these offer some advantages over bacterial expression systems. However, for gene therapy purposes, there are still safety issues to be addressed.

References

Mar 23, 1990·Science·J A WolffP L Felgner
Sep 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·S N YaoK Kurachi
Dec 1, 1994·Vaccine·I Danko, J A Wolff
Nov 22, 1994·Proceedings of the National Academy of Sciences of the United States of America·S K TripathyJ M Leiden
Jul 1, 1995·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·E J Battegay
Jun 11, 1996·Proceedings of the National Academy of Sciences of the United States of America·S KochanekC T Caskey
Jul 1, 1996·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·M Lepäntalo, E Tukiainen
Sep 1, 1996·Nature Medicine·V M RiveraM Gilman
Aug 1, 1996·Cardiovascular Research·L J FeldmanG Steg
Nov 1, 1996·Human Molecular Genetics·Y YangJ M Wilson
Feb 3, 1997·FEBS Letters·G GregoriadisJ B de Souza
Mar 1, 1997·Nature Medicine·K J FisherJ M Wilson
Mar 28, 1997·The Journal of Biological Chemistry·E C McGaryB S Beckman
Sep 1, 1997·Human Molecular Genetics·I DankoJ A Wolff
Apr 21, 1998·Molecular Medicine Today·R G VileR M Diaz
Jul 8, 1998·Proceedings of the National Academy of Sciences of the United States of America·M A MorsyC T Caskey
Aug 1, 1998·Journal of Controlled Release : Official Journal of the Controlled Release Society·R J MumperA P Rolland
Sep 22, 1998·Nature Biotechnology·H Aihara, J Miyazaki
Oct 30, 1998·In Vitro Cellular & Developmental Biology. Animal·J A ChromiakH H Vandenburgh
Dec 23, 1998·Proceedings of the National Academy of Sciences of the United States of America·E R Barton-DavisH L Sweeney
Oct 10, 2002·American Journal of Physiology. Cell Physiology·Courtney A PowellHerman H Vandenburgh
Nov 15, 2002·Nature·Erika Check

❮ Previous
Next ❯

Citations

Aug 8, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Anna BaoutinaKerry R Emslie
Jun 3, 2011·Human Gene Therapy·Alice RochardPascal Bigey
Jun 30, 2012·Biochemical and Biophysical Research Communications·Yuanli LiFeng Liu
Feb 21, 2018·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·L L KorsunskayaS V Vlasenko

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

© 2022 Meta ULC. All rights reserved